Posts by: Diana Campelo Delgado

Diana Campelo Delgado

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.

March 30, 2021March 30, 2021

Imara Opens Higher Dose Arms in Phase 2b Trials of IMR-687

News

Imara is opening higher dose arms in two Phase 2b trials assessing the safety and efficacy of IMR-687, its potential therapy for sickle cell disease (SCD) and beta-thalassemia, in patients ... Read more

March 18, 2021March 18, 2021

GBT Welcomes Proposals for ACCEL Grants, Aiding Sickle Cell Community

News

Global Blood Therapeutics (GBT) has opened its grant program — the Access to Excellent Care for Sickle Cell Patients (ACCEL), now in its third year — to proposals supporting programs ... Read more

November 24, 2020November 24, 2020

Gates Foundation Funds Studies Into CRISPR/Cas9 Gene Editing for SCD

News

Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to develop sickle cell disease (SCD) treatments using the CRISPR/Cas9 genome editing technology, the company announced. The approach, ... Read more

November 19, 2020January 28, 2021

ARU-1801 Gene Therapy Granted Orphan Drug Status in EU

News

The European Medicines Agency (EMA) has granted the designation of orphan drug to ARU-1801, an experimental gene therapy being developed by Aruvant, for the treatment of sickle cell disease (SCD). The decision, based ... Read more